A lawsuit has been lodged towards JPMorgan Chase & Co. JPM by its staff, who declare that the corporate’s prescription drug plan, overseen by CVS Well being Corp. CVS, consented to pay exorbitant costs for drugs.
What Occurred: In accordance with a report, the lawsuit alleges that JPMorgan mishandled well being advantages. One instance cited within the case reveals the plan paying over $6,000 for a a number of sclerosis drug that could possibly be bought for about $30 at retail pharmacies.
The plaintiffs, which embody one present and two former staff, contend that this “systematic mismanagement” resulted in “grossly inflated” medicine prices for these enrolled within the plan.
In accordance with the report by Bloomberg, this lawsuit is a part of an rising sample of comparable instances towards main employers akin to Johnson & Johnson JNJ and Wells Fargo & Co. WFC.
These instances are inspecting the function of employers within the escalating healthcare prices within the US and the income of pharmacy profit managers like CVS.
Additionally Learn: Right here’s The Jaw-Dropping Complete JPMorgan Chase Paid To Battle Authorized Battles Over Two Years
The lawsuit alleges that JPMorgan breached its fiduciary duties beneath the Worker Retirement Revenue Safety Act, which regulates giant employers’ profit plans. The case additionally highlights cases the place JPMorgan’s plan from CVS Well being had considerably larger costs than what sufferers would pay with out insurance coverage.
As of now, JPMorgan has not responded to requests for remark, and a CVS spokesperson declined to remark. The case, Seth Stern et al v. JPMorgan Chase & Co. et al, 25-cv-02097, has been filed within the Southern District of New York.
Why It Issues: This lawsuit underscores the continuing debate concerning the function of employers and pharmacy profit managers within the rising prices of healthcare within the US.
The end result of this case may doubtlessly affect how different corporations handle their worker well being advantages, significantly in relation to prescription drug prices.
It additionally raises questions concerning the transparency and equity of pricing within the pharmaceutical trade.
Learn Subsequent
US Banks Are Abruptly Freezing Accounts — This is How You Can Save Yours
Picture: Shutterstock
Momentum54.53
Development75.84
High quality17.53
Worth39.74
Market Information and Information delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
